Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Nelson, Michael P ^a   Tse, Tonia E ^a,b   O'Quinn, Darrel B ^a   Percival, Stefanie M ^a   Jaimes, Edgar A ^b,c   Warnock, David G ^c   Shacka, John J ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Brain; Electron microscopy; Immunohistochemistry; Neurodegeneration; Neuropathology; Galactosidase A; synuclein

Indexed keywords

ALPHA GALACTOSIDASE; ALPHA SYNUCLEIN; LAMP1 PROTEIN, MOUSE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; MAP1LC3 PROTEIN, MOUSE; MICROTUBULE ASSOCIATED PROTEIN;

ANIMAL; AUTOPHAGY; BRAIN; CELL INCLUSION; COMPLICATION; DISEASE MODEL; ELECTRON MICROSCOPY; FABRY DISEASE; FLUORESCENCE IMAGING; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LYSOSOME; METABOLISM; MOUSE; NERVE DEGENERATION; PATHOLOGY; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

ALPHA-GALACTOSIDASE; ALPHA-SYNUCLEIN; ANIMALS; AUTOPHAGY; BRAIN; DISEASE MODELS, ANIMAL; FABRY DISEASE; GENE EXPRESSION REGULATION; INCLUSION BODIES; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; LYSOSOMES; MICE; MICE, KNOCKOUT; MICROSCOPY, ELECTRON; MICROTUBULE-ASSOCIATED PROTEINS; NERVE DEGENERATION; OPTICAL IMAGING; SIGNAL TRANSDUCTION;

EID: 84921308246     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-2-20     Document Type: Article

References (60)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L: Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967, 276(21):1163-1167. 10.1056/NEJM196705252762101
2. Askari H, Kaneski CR, Semino-Mora C, Desai P, Ang A, Kleiner DE, Perlee LT, Quezado M, Spollen LE, Wustman BA, Schiffmann R: Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch: Int J Pathol 2007, 451(4):823-834. doi:10.1007/s00428-007-0468-6 10.1007/s00428-007-0468-6
3. Schiffmann R: Fabry disease. Pharmacol Therapeut 2009, 122(1):65-77. doi:10.1016/j.pharmthera.2009.01.003 10.1016/j.pharmthera.2009.01.003
4. Burlina A, Sims K, Politei J, Bennett G, Baron R, Sommer C, Møller A, Hilz M: Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol 2011, 11: 61. doi:10.1186/1471-2377-11-61 10.1186/1471-2377-11-61
5. Mehta A, Beck M, Sunder-Plassmann G: Fabry disease: perspectives from 5 years of FOS. Oxford, England: Oxford PharmaGenesis; 2006.
6. Sims K, Politei J, Banikazemi M, Lee P: Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke; J Cereb Circ 2009, 40(3):788-794. doi:10.1161/STROKEAHA.108.526293 10.1161/STROKEAHA.108.526293
7. Mitsias P, Levine S: Cerebrovascular complications of Fabry's disease. Ann Neurol 1996, 40(1):8-17. doi:10.1002/ana.410400105 10.1002/ana.410400105
8. Bersano A, Lanfranconi S, Valcarenghi C, Bresolin N, Micieli G, Baron P: Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy. Acta Neurol Scand 2012, 126(2):77-97. doi:10.1111/j.1600-0404.2012.01661.x 10.1111/j.1600-0404.2012.01661.x
9. Moore D, Altarescu G, Barker W, Patronas N, Herscovitch P, Schiffmann R: White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003, 62(3):231-240. 10.1016/j.brainresbull.2003.09.021
10. Tagliavini F, Pietrini V, Gemignani F, Lechi A, Pallini R, Federico A: Anderson-Fabry's disease: neuropathological and neurochemical investigation. Acta Neuropathol 1982, 56(2):93-98. doi:10.1007/BF00690579 10.1007/BF00690579
11. Loos B, Engelbrecht A-M, Lockshin R, Klionsky D, Zakeri Z: The variability of autophagy and cell death susceptibility: Unanswered questions. Autophagy 2013, 9(9):1270-1285. 10.4161/auto.25560
12. Lum J, DeBerardinis R, Thompson C: Autophagy in metazoans: cell survival in the land of plenty. Nature Rev Mol Cell Biol 2005, 6(6):439-448. doi:10.1038/nrm1660 10.1038/nrm1660
13. Shacka JJ: Lysosome storage disorders on the brain: the autophagy-lysosome pathway contributes to disease pathophysiology and may be utilized for therapeutic benefit. In Autophagy of the nervous system. Edited by: Yue Z, Chu CT. Singapore: World Scientific; 2011:331-354.
14. Chévrier M, Brakch N, Céline L, Gent D, Ramdani Y, Moll S, Djavaheri-Mergny M, Brasse-Lagnel C, Laquerriere A, Barbey F, Bekri S: Autophagosome maturation is impaired in Fabry Disease. Autophagy 2010, 6(5):589-599. doi:10.4161/auto.6.5.11943 10.4161/auto.6.5.11943
15. Uchino M, Uyama E, Kawano H, Hokamaki J, Kugiyama K, Murakami Y, Yasue H, Ando M: A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier. Acta Neuropathol 1995, 90(3):334-338. doi:10.1007/BF00296520 10.1007/BF00296520
16. Eitzman D, Bodary P, Shen Y, Khairallah C, Wild S, Abe A, Shaffer-Hartman J, Shayman J: Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol: JASN 2003, 14(2):298-302. 10.1097/01.ASN.0000043901.45141.D4
17. Nguyen Dinh Cat A, Escoubet B, Agrapart V, Griol-Charhbili V, Schoeb T, Feng W, Jaimes E, Warnock D, Jaisser F: Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease. PloS One 2012, 7(5): doi:10.1371/journal.pone.0033743
18. Ohshima T: alpha -Galactosidase A deficient mice: a model of fabry disease. Proceedings of the National Academy of Sciences 94 1997. doi:10.1073/pnas.94.6.2540
19. Rodrigues L, Ferraz M, Rodrigues D, Pais-Vieira M, Lima D, Brady R, Sousa M, Sá-Miranda M: Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice. Neurobiol Dis 2009, 33(1):48-56. doi:10.1016/j.nbd.2008.09.001 10.1016/j.nbd.2008.09.001
20. Valbuena C, Oliveira J, Carneiro F, Relvas S, Ganhão M, Sá-Miranda M, Rodrigues L: Kidney histologic alterations in α-Galactosidase-deficient mice. Virchows Arch: Int J Pathol 2011, 458(4):477-486. doi:10.1007/s00428-011-1051-8 10.1007/s00428-011-1051-8
21. Ziegler R, Yew N, Li C, Cherry M, Berthelette P, Romanczuk H, Ioannou Y, Zeidner K, Desnick R, Cheng S: Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum Gene Ther 1999, 10(10):1667-1682. doi:10.1089/10430349950017671?2 10.1089/10430349950017671
22. Pompey SN, Michaely P, Luby-Phelps K: Quantitative fluorescence co-localization to study protein-receptor complexes. Methods Mol Biol (Clifton, NJ) 2013, 1008: 439-453. doi:10.1007/978-1-62703-398-5_16 10.1007/978-1-62703-398-5_16
23. Klionsky D, Abdalla F, Abeliovich H, Abraham R, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso J, Ahn H, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes H, Al-Zeer M, Albert M, Albin R, Alegre-Abarrategui J, Aleo M, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer A, Andrieu-Abadie N, et al.: Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012, 8(4):445-544. 10.4161/auto.19496
24. Mader B, Pivtoraiko V, Flippo H, Klocke B, Roth K, Mangieri L, Shacka J: Rotenone inhibits autophagic flux prior to inducing cell death. ACS Chem Neurosci 2012, 3(12):1063-1072. doi:10.1021/cn300145z 10.1021/cn300145z
25. Shacka J: Mouse models of neuronal ceroid lipofuscinoses: useful pre-clinical tools to delineate disease pathophysiology and validate therapeutics. Brain Res Bull 2012, 88(1):43-57. doi:10.1016/j.brainresbull.2012.03.003 10.1016/j.brainresbull.2012.03.003
26. Härtig W, Reichenbach A, Voigt C, Boltze J, Bulavina L, Schuhmann M, Seeger J, Schusser G, Freytag C, Grosche J: Triple fluorescence labelling of neuronal, glial and vascular markers revealing pathological alterations in various animal models. J Chem Neuroanat 2009, 37(2):128-138. doi:10.1016/j.jchemneu.2008.10.003 10.1016/j.jchemneu.2008.10.003
27. Cullen V, Sardi S, Ng J, Xu Y-H, Sun Y, Tomlinson J, Kolodziej P, Kahn I, Saftig P, Woulfe J, Rochet J-C, Glicksman M, Cheng S, Grabowski G, Shihabuddin L, Schlossmacher M: Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol 2011, 69(6):940-953. doi:10.1002/ana.22400 10.1002/ana.22400
28. Mazzulli J, Xu Y-H, Sun Y, Knight A, McLean P, Caldwell G, Sidransky E, Grabowski G, Krainc D: Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146(1):37-52. doi:10.1016/j.cell.2011.06.001 10.1016/j.cell.2011.06.001
29. Pivtoraiko V, Harrington A, Mader B, Luker A, Caldwell G, Caldwell K, Roth K, Shacka J: Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction. J Neurochem 2010, 114(4):1193-1204. doi:10.1111/j.1471-4159.2010.06838.x
30. Qiao L, Hamamichi S, Caldwell K, Caldwell G, Yacoubian T, Wilson S, Xie Z-L, Speake L, Parks R, Crabtree D, Liang Q, Crimmins S, Schneider L, Uchiyama Y, Iwatsubo T, Zhou Y, Peng L, Lu Y, Standaert D, Walls K, Shacka J, Roth K, Zhang J: Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain 2008, 1: 17. doi:10.1186/1756-6606-1-17 10.1186/1756-6606-1-17
31. Sevlever D, Jiang P, Yen S-HC: Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 2008, 47(36):9678-9687. doi:10.1021/bi800699v 10.1021/bi800699v
32. Chen L, Feany M: Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005, 8(5):657-663. doi:10.1038/nn1443 10.1038/nn1443
33. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M, Shen J, Takio K, Iwatsubo T: alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002, 4(2):160-164. doi:10.1038/ncb748
34. Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee V, Trojanowski J, Mann D, Iwatsubo T: Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem 2002, 277(50):49071-49076. doi:10.1074/jbc.M208046200 10.1074/jbc.M208046200
35. Tofaris G, Razzaq A, Ghetti B, Lilley K, Spillantini M: Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003, 278(45):44405-44411. doi:10.1074/jbc.M308041200 10.1074/jbc.M308041200
36. Yang Y, Coleman M, Zhang L, Zheng X, Yue Z: Autophagy in axonal and dendritic degeneration. Trends Neurosci 2013, 36(7):418-428. doi:10.1016/j.tins.2013.04.001 10.1016/j.tins.2013.04.001
37. Pivtoraiko V, Stone S, Roth K, Shacka J: Oxidative stress and autophagy in the regulation of lysosome-dependent neuron death. Antioxid Redox Signal 2009, 11(3):481-496. doi:10.1089/ars.2008.2263 10.1089/ars.2008.2263
38. Shacka J, Klocke B, Young C, Shibata M, Olney J, Uchiyama Y, Saftig P, Roth K: Cathepsin D deficiency induces persistent neurodegeneration in the absence of Bax-dependent apoptosis. J Neurosci: J Soc Neurosci 2007, 27(8):2081-2090. doi:10.1523/JNEUROSCI.5577-06.2007 10.1523/JNEUROSCI.5577-06.2007
39. Terman A, Brunk U: Oxidative stress, accumulation of biological 'garbage', and aging. Antioxid Redox Signal 2006, 8(1-2):197-204. doi:10.1089/ars.2006.8.197
40. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T: LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000, 19(21):5720-5728. doi:10.1093/emboj/19.21.5720 10.1093/emboj/19.21.5720
41. Liebau M, Braun F, Höpker K, Weitbrecht C, Bartels V, Müller R-U, Brodesser S, Saleem M, Benzing T, Schermer B, Cybulla M, Kurschat C: Dysregulated autophagy contributes to podocyte damage in Fabry's disease. PloS one 2013, 8(5): doi:10.1371/journal.pone.0063506
42. Jaber N, Dou Z, Chen J-SS, Catanzaro J, Jiang Y-PP, Ballou LM, Selinger E, Ouyang X, Lin RZ, Zhang J, Zong W-XX: Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function. Proc Natl Acad Sci USA 2012, 109(6):2003-2008. doi:10.1073/pnas.1112848109 10.1073/pnas.1112848109
43. Shibata M, Yoshimura K, Furuya N, Koike M, Ueno T, Komatsu M, Arai H, Tanaka K, Kominami E, Uchiyama Y: The MAP1-LC3 conjugation system is involved in lipid droplet formation. Biochem Biophys Res Commun 2009, 382(2):419-423. doi:10.1016/j.bbrc.2009.03.039 10.1016/j.bbrc.2009.03.039
44. Keilani S, Lun Y, Stevens A, Williams H, Sjoberg E, Khanna R, Valenzano K, Checler F, Buxbaum J, Yanagisawa K, Lockhart D, Wustman B, Gandy S: Lysosomal dysfunction in a mouse model of Sandhoff disease leads to accumulation of ganglioside-bound amyloid-β peptide. J Neurosci: J Soc Neurosci 2012, 32(15):5223-5236. doi:10.1523/JNEUROSCI.4860-11.2012 10.1523/JNEUROSCI.4860-11.2012
45. Lee H-J, Khoshaghideh F, Patel S, Lee S-J: Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci: J Soc Neurosci 2004, 24(8):1888-1896. doi:10.1523/JNEUROSCI.3809-03.2004 10.1523/JNEUROSCI.3809-03.2004
46. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L: Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem 2008, 283(35):23542-23556. doi:10.1074/jbc.M801992200 10.1074/jbc.M801992200
47. Yang Q, She H, Gearing M, Colla E, Lee M, Shacka J, Mao Z: Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science (New York, NY) 2009, 323(5910):124-127. doi:10.1126/science.1166088 10.1126/science.1166088
48. Kolter T, Sandhoff K: Sphingolipid metabolism diseases. Biochim Biophys Acta 2006, 1758(12):2057-2079. doi:10.1016/j.bbamem.2006.05.027 10.1016/j.bbamem.2006.05.027
49. Gegg M, Burke D, Heales S, Cooper J, Hardy J, Wood N, Schapira A: Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012, 72(3):455-463. doi:10.1002/ana.23614 10.1002/ana.23614
50. Lwin A, Orvisky E, Goker-Alpan O, LaMarca M, Sidransky E: Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004, 81(1):70-73. 10.1016/j.ymgme.2003.11.004
51. Buechner S, De Cristofaro M, Ramat S, Borsini W: Parkinsonism and Anderson Fabry's disease: a case report. Movement Disord: J Movement Disord Soc 2006, 21(1):103-107. doi:10.1002/mds.20675 10.1002/mds.20675
52. Wu G, Huang J, Feng X, Zhang A, Li J, Pang S, Gu K, Dong H, Zhang J, Gao H, Yan B: Decreased expression of lysosomal alpha-galactosiase A gene in sporadic Parkinson's disease. Neurochem Res 2011, 36(10):1939-1944. doi:10.1007/s11064-011-0516-0 10.1007/s11064-011-0516-0
53. Wu G, Pang S, Feng X, Zhang A, Li J, Gu K, Huang J, Dong H, Yan B: Genetic analysis of lysosomal alpha-galactosidase A gene in sporadic Parkinson's disease. Neuroscience Lett 2011, 500(1):31-35. doi:10.1016/j.neulet.2011.05.238 10.1016/j.neulet.2011.05.238
54. Wu G, Yan B, Wang X, Feng X, Zhang A, Xu X, Dong H: Decreased activities of lysosomal acid alpha-D-galactosidase A in the leukocytes of sporadic Parkinson's disease. J Neurol Sci 2008, 271(1-2):168-173. doi:10.1016/j.jns.2008.04.011
55. Kolling G, Obata F, Gross L, Obrig T: Immunohistologic techniques for detecting the glycolipid Gb(3) in the mouse kidney and nervous system. Histochem Cell Biol 2008, 130(1):157-164. doi:10.1007/s00418-008-0417-8 10.1007/s00418-008-0417-8
56. Schueler U, Kolter T, Kaneski C, Blusztajn J, Herkenham M, Sandhoff K, Brady R: Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis 2003, 14(3):595-601. 10.1016/j.nbd.2003.08.016
57. Sun Y, Liou B, Ran H, Skelton M, Williams M, Vorhees C, Kitatani K, Hannun Y, Witte D, Xu Y-H, Grabowski G: Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet 2010, 19(6):1088-1097. doi:10.1093/hmg/ddp580 10.1093/hmg/ddp580
58. Sun Y, Ran H, Zamzow M, Kitatani K, Skelton M, Williams M, Vorhees C, Witte D, Hannun Y, Grabowski G: Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse. Hum Mol Genet 2010, 19(4):634-647. doi:10.1093/hmg/ddp531 10.1093/hmg/ddp531
59. Schirmer L, Merkler D, König F, Brück W, Stadelmann C: Neuroaxonal regeneration is more pronounced in early multiple sclerosis than in traumatic brain injury lesions. Brain Pathol (Zurich, Switzerland) 2013, 23(1):2-12. doi:10.1111/j.1750-3639.2012.00608.x 10.1111/j.1750-3639.2012.00608.x
60. Reisin R, Romero C, Marchesoni C, Nápoli G, Kisinovsky I, Cáceres G, Sevlever G: Brain MRI findings in patients with Fabry disease. J Neurol Sci 2011, 305(1-2):41-44. doi:10.1016/j.jns.2011.03.020